MaxCyte signs licensing deal with Apeiron Biologics
By Josh White
Date: Wednesday 08 Jul 2020
(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licensing agreement with immunotherapy biotechnology firm Apeiron Biologics on Wednesday, under which Apeiron would obtain non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.
The AIM-traded firm said they would be used to advance 'APN401' - a siRNA-based cell therapy currently in clinical development for various solid tumours.
In return, MaxCyte would receive undisclosed development and approval milestones and sales-based payments, in addition to other licensing fees.
"We are proud to support Apeiron in the development of a siRNA-based treatment that could help patients facing cancers with various forms of tumours," said president and chief executive officer Doug Doerfler.
"This agreement represents an important achievement for MaxCyte, and highlights the value of our next-generation technology platform to companies across the globe seeking to unlock the potential of their engineered cell therapy programs."
At 1328 BST, shares in MaxCyte were up 4.14% at 208.8p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN